Related Experiment Video

Updated: Aug 9, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Mechanisms leading to the development of hormone-resistant prostate cancer

Susan Kasper1, Michael S Cookson

  • 1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232-2765, USA. susan.kasper@vanderbilt.edu

The Urologic Clinics of North America
|April 25, 2006
PubMed

Insights

Advanced prostate cancer becomes lethal when it develops hormone resistance. Understanding androgen receptor reactivation, cancer stem cells, and epithelial-mesenchymal transition is key to developing new treatments for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Advanced and metastatic prostate cancer are lethal despite androgen deprivation therapy (ADT).
  • Hormone resistance leads to disease progression and mortality in prostate cancer patients.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the mechanisms of hormone resistance in advanced prostate cancer.
  • To highlight the role of androgen receptor reactivation, cancer stem cells, and epithelial-mesenchymal transition (EMT) in treatment failure.
  • To emphasize the need for novel therapeutic strategies based on these mechanisms.

Main Methods:

  • Literature review focusing on molecular mechanisms of prostate cancer hormone resistance.
  • Analysis of studies investigating androgen receptor signaling, cancer stem cell properties, and EMT.
  • Synthesis of current knowledge on resistance pathways during ADT.

Main Results:

  • Androgen receptor (AR) reactivation is a primary mechanism of resistance during ADT.
  • Cancer stem cells contribute to tumor recurrence and resistance to therapy.
  • Epithelial-mesenchymal transition (EMT) enhances the metastatic potential of prostate cancer cells.

Conclusions:

  • Hormone resistance in advanced prostate cancer involves complex molecular pathways.
  • Targeting AR reactivation, cancer stem cells, and EMT may overcome treatment resistance.
  • Further research into these mechanisms is essential for developing effective therapies for lethal prostate cancer.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...